Surrozen, Inc.
SRZN- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001824893
In the last 90 days, Surrozen, Inc. insiders filed 0 open-market purchases and 1 sale; 70 institutions reported holding it in 13F filings for Q2 2026, worth $314.5M in total; no superinvestor holds it.
13F holders, Q3 2024
Institutional positions in Surrozen, Inc. as of Sep 30, 2024. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 23
- +4 vs. Q2 2024
- Shares held
- 2.13M
- +96.0K (+4.7%) vs. Q2 2024
- Total value
- $25.5M
- +$3.20M (+14.4%) vs. Q2 2024
- New holders
- 6
- 4 more added
- Sold out
- 2
- 4 more reduced
2 institutions that held it in Q2 2024 haven't filed for Q3 2024 yet. Not filing isn't selling, so they aren't counted as sold out or in the changes above.
Compare with Q2 2024: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting SRZN on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 70 | $314.5M |
| Q1 2026 | 59 | $314.2M |
| Q4 2025 | 55 | $195.1M |
| Q3 2025 | 36 | $81.7M |
| Q2 2025 | 31 | $53.9M |
| Q1 2025 | 30 | $63.5M |
| Q4 2024 | 24 | $35.4M |
| Q3 2024 | 23 | $25.5M |
| Q2 2024 | 21 | $23.1M |
| Q1 2024 | 16 | $15.0M |
| Q4 2023 | 17 | $9.78M |
| Q3 2023 | 25 | $7.90M |
| Q2 2023 | 22 | $8.62M |
| Q1 2023 | 23 | $9.91M |
| Q4 2022 | 26 | $9.36M |
| Q3 2022 | 27 | $44.1M |
| Q2 2022 | 24 | $63.1M |
| Q1 2022 | 30 | $67.4M |
| Q4 2021 | 32 | $153.5M |
| Q3 2021 | 29 | $150.7M |
| Q2 2021 | 0 | $0 |
| Q1 2021 | 0 | $0 |
Institutions, Q3 2024
Shares, value and share of portfolio for each institution holding Surrozen, Inc.; share changes are against Q2 2024.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| The Column Group LLC | 810,088 | $9.70M | 13.95% | 00.0% | Unchanged |
| Ra Capital Management, L.P. | 282,580 | $3.39M | 0.04% | 00.0% | Unchanged |
| Nantahala Capital Management, LLC | 187,206 | $2.24M | 0.19% | 00.0% | Unchanged |
| StemPoint Capital LP | 182,918 | $2.19M | 0.66% | +39,408+27.5% | Added |
| Armistice Capital, LLC | 139,000 | $1.67M | 0.04% | −51,000−26.8% | Reduced |
| Stonepine Capital Management, LLC | 110,000 | $1.32M | 0.83% | +43,916+66.5% | Added |
| Euclidean Capital LLC | 87,696 | $1.05M | 0.12% | 00.0% | Unchanged |
| Vanguard Group Inc | 65,135 | $766.6K | 0.00% | +4,300+7.1% | Added |
| ArrowMark Colorado Holdings LLC | 55,123 | $648.8K | 0.01% | 00.0% | Unchanged |
| Board of Trustees of The Leland Stanford Junior University | 52,130 | $624.5K | 0.05% | 00.0% | Unchanged |
| Morgan Stanley | 35,211 | $421.8K | 0.00% | 00.0% | Unchanged |
| Heights Capital Management, Inc | 29,999 | $353.1K | 0.26% | +29,999 | New |
| Price T Rowe Associates Inc | 21,715 | $256.0K | 0.00% | +21,715 | New |
| Alyeska Investment Group, L.P. | 20,376 | $244.1K | 0.00% | 00.0% | Unchanged |
| Geode Capital Management, LLC | 17,761 | $209.1K | 0.00% | −947−5.1% | Reduced |
| Renaissance Technologies LLC | 13,826 | $165.6K | 0.00% | +1,400+11.3% | Added |
| Citadel Advisors LLC | 10,930 | $128.6K | 0.00% | +10,930 | New |
| BlackRock, Inc. | 8,211 | $98.4K | 0.00% | +8,211 | New |
| Tower Research Capital LLC (TRC) | 455 | $5.45K | 0.00% | +455 | New |
| Wolverine Asset Management LLC | 281 | $3.37K | 0.00% | 00.0% | Unchanged |
| Barclays PLC | 25 | $300 | 0.00% | +25 | New |
| Bank of America Corp | 16 | $192 | 0.00% | −4−20.0% | Reduced |
| JPMorgan Chase & Co | 6 | $71 | 0.00% | −1−14.3% | Reduced |
| UBS Group AG | 0 | $0 | 0.00% | −12,027−100.0% | Sold out |
| Royal Bank of Canada | 0 | $0 | 0.00% | −338−100.0% | Sold out |
| CVI Holdings, LLC | – | – | – | – | Not filed |
| BlackRock Inc. | – | – | – | – | Not filed |